Detection of antibody–drug conjugate-induced interstitial lung disease using circulating cell-free DNA
The increasing use and anticipated future adoption of antibody–drug conjugates (ADCs) present a significant challenge in identifying and monitoring patients for the development of potentially fatal drug-induced interstitial lung disease (ILD). We sought to apply a tissue-specific methylation analysis of circulating cell-free DNA (cfDNA) to measure lung damage in patients with trastuzumab deruxtecan (T-DXd)-related ILD.